Tag: Pembrolizumab

FDA Approval of Immunotherapy For MSI-High or Mismatch Repair Deficient Tumors

| June 5, 2017 | 0 Comments

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have progressed following prior treatment. KEYTRUDA has also been approved fro MSI-H or dMMR colorectal cancers that have progressed following treatment with conventional chemotherapies. The immunooncology/immunotherapy story is fascinating. […]

Continue Reading

Indica Labs’ HALO Software Used as Quantitative Analysis Platform in Ground Breaking Melanoma Drug Study Published in Nature

| December 3, 2014 | 0 Comments

New Mexico, USA 12/2/2014 – Indica Labs announced today that its HALO™ image analysis platform was used to quantify predictive biomarkers in a ground breaking study of the melanoma drug, pembrolizumab. Pembrolizumab is an immunotherapy drug that works by blocking PD-1, a protein which prevents T cells from attacking melanoma cells.  Approximately one in three […]

Continue Reading